BioSpace News Archive

Novavax, Inc., a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the second quarter ended June 30, 2020.

ANI Pharmaceuticals, Inc. announced the appointments of Jeanne Thoma, President and Chief Executive Officer of SPI Pharma, Inc. and Antonio Pera, former President of Par Pharmaceutical to the ANI Pharmaceuticals Board of Directors.

Madrigal Pharmaceuticals, Inc. announced its second quarter 2020 financial results and highlights

Cardinal Health reported fourth quarter fiscal year 2020 revenues of $36.7 billion, a decrease of 2 percent from the fourth quarter last year.

ANI Pharmaceuticals, Inc. announced business highlights and financial results for the three and six months ended June 30, 2020.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: BTIG Virtual Biotechnology Conference 2020 Tuesday, August 11, 2020 at 1:00 p.m. ET Canaccord Genuity 40 th Annual Growth Conference Thursday, August 13, 2020 at 1:30

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Thursday, August 13, 2020. During the call, R. Bryan Riggsbee, interim president and CEO and chief financial officer, and Scott Gleason, senior vice president of Investor Relations and Corporate Strategy, will

Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track Continued momentum in building commercialization infrastructure and supply chain for Oral Paclitaxel Announced two financing agreements for up to $275 million in aggregate Product sales guidance for 2020 raised to mid-teens percentage growth y/y Conference call and live webcast at 8.00am ET today

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announced the appointment of Jennifer L. Aaker, Ph.D. to its board of directors, expanding membership to nine directors. Dr. Aaker is the General Atlantic Professor at the Stanford Graduate School of Business, and a leading behavioral scientist, scholar, and best-selling author. Her unique expertise helps companies and leaders bu